Nabriva Therapeutics (NBRV)
NASDAQ: NBRV
· Real-Time Price · USD
1.42
0.01 (0.71%)
At close: Jul 31, 2023, 10:00 PM
Nabriva Therapeutics Revenue Breakdown
| Period Ending | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
|---|---|---|---|---|---|---|---|---|
| Collaboration revenue Revenue | 29K | 60K | 141K | 96K | 629K | 453K | 562K | 813K |
| Collaboration revenue Revenue Growth | -51.67% | -57.45% | +46.88% | -84.74% | +38.85% | -19.40% | -30.87% | n/a |
| Product revenue, net Revenue | 7.56M | 10.38M | 8.64M | 8.68M | 7.04M | n/a | n/a | n/a |
| Product revenue, net Revenue Growth | -27.15% | +20.09% | -0.43% | +23.30% | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 9M | 9.61M | 11.91M | 11.05M | 12.7M | 14.49M | 12.26M | 12.85M | 12.05M | 17.52M | 11M | 8.07M | 16.02M | 17.15M | 18.5M | 13.43M | 13.41M | 10.19M | 12.58M | 8.84M | 10.14M | 10.16M | 9.53M | 5.53M | 4.17M | 4.03M | 2.96M | 3.37M | 3.08M | 1.35M | 1.78M | 1.65M | 883.66K |
| Selling, General, and Administrative Revenue Growth | -6.33% | -19.29% | +7.78% | -13.02% | -12.34% | +18.21% | -4.65% | +6.70% | -31.25% | +59.33% | +36.24% | -49.63% | -6.54% | -7.33% | +37.80% | +0.13% | +31.62% | -19.03% | +42.38% | -12.82% | -0.23% | +6.66% | +72.34% | +32.38% | +3.73% | +36.07% | -12.17% | +9.17% | +128.52% | -23.99% | +7.96% | +86.16% | n/a |
| Research and Development Revenue | 2.63M | 2.63M | 4.03M | 4.09M | 3.52M | 2.39M | 3.22M | 3.15M | 3.87M | 2.84M | 3.49M | 6.5M | 4.94M | 5.2M | 5.6M | 8.07M | 7.54M | 21.49M | 40.8M | 9.72M | 10.28M | 13.24M | 12.67M | 11.04M | 12.66M | 13.09M | 12.06M | 9.83M | 13.02M | 7.1M | 7.87M | 4.76M | 2.72M |
| Research and Development Revenue Growth | -0.04% | -34.87% | -1.37% | +16.24% | +47.09% | -25.77% | +2.25% | -18.56% | +36.15% | -18.50% | -46.37% | +31.47% | -4.96% | -7.12% | -30.63% | +7.11% | -64.92% | -47.34% | +319.92% | -5.47% | -22.39% | +4.55% | +14.72% | -12.77% | -3.28% | +8.54% | +22.70% | -24.50% | +83.34% | -9.75% | +65.27% | +74.94% | n/a |